Article ; Online: Nonclinical Investigation of Cytokine Mitigation Strategies for T-cell-Engaging Bispecifics in the Cynomolgus Macaque.
Journal of immunotherapy (Hagerstown, Md. : 1997)
2024 Volume 47, Issue 5, Page(s) 160–171
Abstract: Summary: T-cell-directed cancer therapies such as T-cell-engaging bispecifics (TCBs) are commonly associated with cytokine release syndrome and associated clinical signs that can limit their tolerability and therapeutic benefit. Strategies for reducing ... ...
| Abstract | Summary: T-cell-directed cancer therapies such as T-cell-engaging bispecifics (TCBs) are commonly associated with cytokine release syndrome and associated clinical signs that can limit their tolerability and therapeutic benefit. Strategies for reducing cytokine release are therefore needed. Here, we report on studies performed in cynomolgus monkeys to test different approaches for mitigating cytokine release with TCBs. A "priming dose" as well as subcutaneous dosing reduced cytokine release compared with intravenous dosing but did not affect the intended T-cell response to the bispecific. As another strategy, cytokines or cytokine responses were blocked with an anti-IL-6 antibody, dexamethasone, or a JAK1/TYK2-selective inhibitor, and the effects on toxicity as well as T-cell responses to a TCB were evaluated. The JAK1/TYK2 inhibitor and dexamethasone prevented CRS-associated clinical signs on the day of TCB administration, but the anti-IL-6 had little effect. All interventions allowed for functional T-cell responses and expected damage to target-bearing tissues, but the JAK1/TYK2 inhibitor prevented the upregulation of activation markers on T cells, suggesting the potential for suppression of T-cell responses. Our results suggest that short-term prophylactic dexamethasone treatment may be an effective option for blocking cytokine responses without affecting desired T-cell responses to TCBs. |
|---|---|
| MeSH term(s) | Animals ; Macaca fascicularis ; Antibodies, Bispecific/pharmacology ; T-Lymphocytes/immunology ; T-Lymphocytes/drug effects ; T-Lymphocytes/metabolism ; Cytokines/metabolism ; Dexamethasone/pharmacology ; Humans ; Cytokine Release Syndrome/drug therapy ; Cytokine Release Syndrome/etiology ; Interleukin-6/metabolism ; Lymphocyte Activation/drug effects ; Lymphocyte Activation/immunology ; Neoplasms/immunology ; Neoplasms/drug therapy |
| Chemical Substances | Antibodies, Bispecific ; Cytokines ; Dexamethasone (7S5I7G3JQL) ; Interleukin-6 |
| Language | English |
| Publishing date | 2024-04-02 |
| Publishing country | United States |
| Document type | Journal Article ; Research Support, Non-U.S. Gov't |
| ZDB-ID | 1064067-8 |
| ISSN | 1537-4513 ; 1053-8550 ; 1524-9557 |
| ISSN (online) | 1537-4513 |
| ISSN | 1053-8550 ; 1524-9557 |
| DOI | 10.1097/CJI.0000000000000512 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 1778: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.